Pharmicell Co.,Ltd.

Biopharma firm in stem cell therapies, biochemicals, cell banking, and stem cell cosmetics.

005690 | KO

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: South Korea
Address:: 서울특별시 강남구 언주로 874 (신사동, 쌍봉빌딩 7층), 강남구
Website:: https://www.pharmicell.com/eng/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology. The company is a pioneer in the field, having developed and commercialized Hearticellgram®-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its business is diversified across four main segments: stem cell therapeutics, including ongoing research for conditions like liver disease; a biochemical division that conducts oligonucleotide synthesis and produces nucleosides, mPEGs, and pharmaceutical intermediates; a stem cell banking business for adult and cord blood ('Twelve' brand); and a line of cosmetics derived from stem cell culture media ('By Pharmicell lab' brand).

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Pharmicell Co.,Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Pharmicell Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pharmicell Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Eisai Co., Ltd. A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.	Japan	4523
Elicera Therapeutics AB Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.	Sweden	ELIC
Ellen AB Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.	Sweden	ELN
Enlivex Therapeutics Ltd. Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.	Israel	ENLV
Enorama Pharma AB Develops & makes consumer nicotine products & medicated gums, offering private label solutions.	Sweden	ERMA
ENZYCHEM LIFESCIENCES CORPORATION Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.	South Korea	183490
Enzymatica AB Develops medical devices with patented enzyme technology to treat upper respiratory infections.	Sweden	ENZY
Epi Biotech Co., Ltd. Developing alopecia therapies, skin regeneration products, and preclinical CRO services.	South Korea	446440
EQL Pharma AB Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.	Sweden	EQL
ERYTECH Pharma S.A. Developing phage therapies to combat antibiotic-resistant bacterial infections.	France	ERYP